Effect of Strength-Based Resilience on Patient's Length of Stay at the Renfrew Center for Eating Disorders
Abstract
OBJECTIVE: Throughout past decades, physicians have sought to understand factors that contribute to severity of an eating disorder (ED). There is a potential relationship between patients' resilience and the recovery course of their disorder. The objective of this study is to examine the correlation between resilience, measured by indicators of mindfulness and restraint, and length of stay (LOS) at Renfrew Center for Eating Disorders.
MATERIALS AND METHODS: Data were obtained from Renfrew's database. Secondary analysis was conducted from this database. The database included women aged 13-75 years admitted to Renfrew. The database excluded males and individuals of ages 75 years old. Resilience was analyzed through Southampton Mindfulness Questionnaire (SMQ) and ED restraint. The dependent variable, LOS at Renfrew, was analyzed by multivariable linear regression, and multivariable logistic regression for LOS >45 days.
RESULTS: A sample of 2901 subjects was analyzed. There were significant associations between increased mindfulness scores and decreased restraint scores and a decreased LOS at Renfrew. For every 13-point increase in SMQ, the LOS was associated with a decrease by ∼1 day, and for every 1-point decrease in the restraint score (increased restraint), the LOS was associated with a decrease by ∼1 day. Higher restraint scores were independently associated with an increase in likelihood of LOS >45 days by 22.8%.
CONCLUSIONS: The Renfrew data support the relationship…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.